To test for neural differentiation efficiency, we performed immunostaining for known NPC markers, and by passage 5 we observed Nestin-positive (97.17% ± 5.17%), PAX6-positive (64.52% ± 19.79%), and SOX-positive (63.62% ± 16.51%) cells among the hiPSC-derived NPC lines (Fig. 2b, c). The gene discussed is PAX6; the disease is nasopharyngeal carcinoma.